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Weller, Melodie L. Ph.D., May 2006 Pharmacology
The role of excitatory amino acid transporters in neuroprotection and neuropa­
thology.
Chairperson: David J. Poulsen, Ph.D.
Glutamate is the most abundant excitatory neurotransmitter found within the 
CNS. Glutamate has been shown to play a prominent role in development, plas­
ticity, learning and memory. Sodium dependent glutamate transporters (EAAT1- 
5) facilitate termination of glutamate signaling. Altered expression profiles and 
function of these transporters have been shown to promote neurodegradation 
and have been implicated in multiple disease states, including amyotrophic lat­
eral sclerosis (ALS), Alzheimer’s disease, stroke, and epilepsy. The two studies 
detailed in this dissertation investigate the role of EAAT2 and EAAC1 (EAAT3) in 
neuroprotection and neuropathology.
Excitatory amino acid transporter 2 (EAAT2) is responsible for up to 90% of all 
glutamate uptake and is primarily localized on astrocytes. Many studies have 
attempted to elevate EAAT2 expression to compensate for loss of function and 
expression in disease. The aim of this study was to isolate and characterize 
the contribution of increased astrocytic EAAT2 expression towards neuroprotec­
tion. A novel recombinant adeno-associated virus, rAAV1-GFAP-EAAT2, was 
designed and used to selectively increase astrocytic EAAT2 expression. Under 
conditions of oxygen glucose deprivation, elevated astrocytic EAAT2 expression 
was shown to offer neuroprotection. This approach offers the first evidence sup­
porting sole regulation of EAAT2 expression in astrocytes and the specific role of 
this transporter in neuroprotection.
Excitatory amino acid carrier 1 (EAAC1) is present throughout the CNS with a 
small percentage being uniquely expressed on inhibitory presynaptic terminals 
and provides a primary source of glutamate for GABA synthesis. Alterations to this 
or other pathways leading to GABA synthesis, may result in abnormal inhibitory 
synaptic transmission, neuronal hyperexcitability and epileptiform activity. Prior 
studies have shown GABA synthesis and signaling were reduced and seizure-like 
behaviors were heightened under global pharmacological inhibition or antisense 
knockdown of EAAC1. We hypothesized that increased GABAergic EAAC1 
expression would enhance GABA synthesis, shift seizure susceptibility, and 
promote neuroprotection. Using recombinant adeno-associated virus vectors, 
we were able to specifically target transgene delivery to GABAergic neurons and 
direct over-expression and knockdown of EAAC1 in vivo. Modulation of GABAergic 
EAAC1 expression resulted in alterations in GABA synthesis, seizure susceptibility 
and neuroprotection.
ii
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Table of Contents
Title Page 
Abstract
Table of Contents 
List of Figures
Chapter One
Introduction 
Chapter Two
“Astrocyte specific over-expression of EAAT2 is
neuroprotective under oxygen glucose 
deprivation conditions.”
Chapter Three
“EAAC1 glutamate transporter activity on inhibitory 
presynaptic terminals modulates GABA synthesis 
and neuroprotection.”
Chapter Four
Conclusion
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
List of Figures 
Chapter Two
Figure 1A Cell type specific expression of rAAV 1-GFAP-hrGFP 26
Figure 2A Western blot analysis of EAAT2 27
Figure 2B Dosimetry analysis of EAAT2 expression 27
Figure 2C Functional EAAT2 mediated [^H] Aspartic Acid 27
Figure 3 OGD mediated neurodamage 28
Chapter Three
Figure 1A Western blot analysis of EAAT3 55
Figure IB Dosimetry analysis of EAAT3 western blot 55
Figure 1C Functional increased EAAT2 expression 55
Figure 2A HPLC analysis of GABA content in HC2S2 cells 56
Figure 2B HPLC analysis of glutamate content in HC2S2 cells 56
Figure 2C HPLC analysis of glutamine content in HC2S2 cells 56
Figure 3A Cell type specific expression of rAAVl/2-GAD65-hrGFP 57
Figure 3B Co-localization of EAAC1 with GAD65 57
Figure 3C Co-localization of flag epitope with GAD65 57
Figure 4 Impact of EAAC1 expression on seizure susceptibility 58
Figure 5A Seizure-mediated neurodamage - Fluoro-Jade B stain 59
Figure 5B Summary of seizure-seizure mediated neurodamage 59
of the hippocampus
Figure 6A Seizure-mediated neurodamage of cortex 60
Figure 6B Summary of seizure mediated neurodamage of cortex 60
iv
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Chapter One
Introduction
1
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The two studies outlined in this dissertation “Astrocyte specific over­
expression of EAAT2 is neuroprotective under oxygen glucose deprivation 
conditions” and “EAAC1 glutamate transporter activity on inhibitory presynaptic 
terminals modulates GABA synthesis and neuroprotection” address the impact of 
altered glutamate transporter expression on neuroprotection and neuropathology 
under seizure and stroke-like conditions. Prior studies have attempted to evaluate 
the role of EAAT2 and EAAC1 through development of transgenic animal models, 
global oligonucleotide antisense knockdown, or general pharmacological inhibition 
but were limited by their inability to alter EAAT2 and EAAC1 expression within the 
hippocampus in a cell type specific manner. Additionally, prior studies have been 
primarily limited to inhibition of glutamate transporter function and lacked the ability 
to evaluate the impact of enhanced expression of selected glutamate transporters 
in a cell type specific manner. The studies outlined in the following two chapters 
utilized a novel approach in evaluating the role of these transporters through 
the use of recombinant adeno-associated viruses (rAAV). The rAAV1-GFAP and 
rAAV1/2-GAD65 viral constructs developed and characterized for these studies 
enabled direct cell type specific modulation of astrocytic EAAT2 and GABAergic 
EAAC1 expression, respectively.
The scope of the research presented in this dissertation were designed to 
address the following aims:
1. Use of rAAV to deliver genes for selected glutamate 
transporters. Sense and antisense gene sequences will 
be used to facilitate over-expression and knockdown of 
transporter expression, respectively.
2. Use selected promoters to facilitate cell type specific 
knockdown and over-expression of selected glutamate
2
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transporters. The GFAP promoter and the GAD65 promoters 
were chosen to drive astrocyte specific EAAT2 expression 
and EAAC1 expression specific to inhibitory presynaptic 
neuron terminals, respectively.
3. Evaluate the influence of selected glutamate transporters on
neuroprotection and neuropathology. The neuroprotective 
role astrocytic EAAT2 over-expression will be evaluated in a 
stroke model. The impact of EAAC1 modulation in GABAergic 
neurons will be evaluated using a pilocarpine induced seizure 
model.
Together these studies offer insight into the potential impact of altered 
glutamate transporter expression in disease processes and associated 
neurodegradation. The novel viruses used in these studies enabled efficient cell 
type specific modulation of glutamate transporters within select subpopulations of 
cells in the hippocampus.
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Chapter Two
Astrocyte specific over-expression of EAAT2 is neuroprotective under oxygen
glucose deprivation conditions.
Melodie L. Weller, Trevor C. Neal, Ida M. Stone, David J. Poulsen
COBRE Center for Structural and Functional Neuroscience, 
Department of Biomedical and Pharmaceutical Sciences,
University of Montana, Missoula, MT 59812
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Abstract
Glutamate is the most abundant excitatory amino acid found within 
the CNS. This neurotransmitter has been shown to play a prominent role in 
development, plasticity, learning and memory. Sodium dependent glutamate 
transporters (EAAT1-5) facilitate termination of glutamate signaling. Excitatory 
amino acid transporter 2 (EAAT2) is responsible for up to 90% of all glutamate 
uptake and is primarily localized on astrocytes. Multiple disease states have 
been associated with alterations in EAAT2 expression level and function. Many 
studies have attempted to elevate EAAT2 expression to compensate for loss of 
function and expression in disease. Elevated EAAT2 expression has been noted 
during ischemic preconditioning (IPC) but is just one of many components altered 
under IPC. The aim of this study was to isolate and characterize the contribution 
of increased astrocytic EAAT2 expression towards neuroprotection. A novel 
recombinant adeno-associated virus, rAAV1-GFAP-EAAT2, was designed and 
used to selectively increase astrocytic EAAT2 expression. Under conditions of 
oxygen glucose deprivation, elevated astrocytic EAAT2 expression was shown 
to offer neuroprotection. This approach offers the first evidence supporting sole 
regulation of EAAT2 expression in astrocytes and the specific role of this transporter 
in neuroprotection.
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Introduction
Glutamate is the most abundant excitatory neurotransmitter in the central 
nervous system (CNS). This neurotransmitter directs activation of ionotropic and 
metabotropic glutamate receptors and mediates secondary pathways involved 
in development, plasticity, learning and memory (Contestabile, 2000; Riedel,
2003). Excessive or prolonged levels of glutamate in the synaptic cleft may lead 
to excitotoxic damage and eventual cell death (Danbolt, 2001; Noraberg, 2005). 
Termination of glutamatergic signaling is mediated by the removal of glutamate 
from the extracellular space by excitatory amino acid transporters (EAATs). To 
date, five EAATs have been identified and exhibit distinct expression patterns 
throughout the CNS. Of these transporters, the high affinity, sodium dependent 
EAAT2 is the most abundant and responsible for more than 90% of all glutamate 
uptake (Danbolt, 1992). EAAT2 is primarily localized to astrocytes, with modest 
expression in neurons (Chen, 2004; Maragakis, 2004).
Multiple neurodegenerative diseases have been linked with glutamate 
-mediated excitotoxicity and altered EAAT2 expression. Amyotrophic lateral 
sclerosis (ALS) affected tissues have decreased EAAT2 expression focused 
in the motor cortex and spinal cord attributed to aberrant RNA processing and 
activated caspase-3 cleavage of EAAT2. (Guo, 2002; Boston-Howes, 2006). 
Similarly, Alzheimer’s disease (AD) affected tissues show a significant loss of 
EAAT2 expression and funcion (Cross, 1987; Li, 1997). Neurodamage mediated 
by ischemia has been show to be exacerbated by decreased astrocytic EAAT2 
expression and function (Rothstein, 1996; Rao, 2001). Though modifications in 
EAAT2 expression are a shared feature of these neurodegenerative diseases, 
altered EAAT2 expression is not the cause of these diseases (Howland 2002).
6
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Increased astrocytic EAAT2 expression offers neuroprotection under 
excitotoxic conditions. Treatment with p-lactam antibiotics renders increased 
EAAT2 expression potentially through mechanisms similar to ischemic 
preconditioning (IPC) (Rothstein, 2005). IPC is characterized by an acute non- 
lethal excitotoxic event that results in altered genomic and proteomic response to a 
secondary excitatory stimulus, p-lactam antibiotics are antagonists of the GABA-A 
receptor and are capable of simulating a mild excitotoxic even through inhibition 
of GABA signaling (Fujimoto, 1995). Individual mediators of IPC, such as TNFa 
convertase, have been shown to indirectly upregulate EAAT2 expression (Romera,
2004).
Astrocytes provide a window of neuroprotection under acute excitotoxic 
events. Ischemia mediated energy depletion causes reversal of EAATs on 
neurons and may promote further excitotoxic damage (Li 1999). Astrocytes 
maintain extended function and ability to continue energy production through 
anaerobic glycolysis, supply of nutrients and antioxidants to neurons, maintenance 
of extracellular pH, and glutamate uptake (Benarroch, 2005). An extended time 
frame of neuroprotection may be afforded by the initial resilience of astrocytes 
under excitotoxic stress.
Studies reporting neuroprotection in the presence of elevated EAAT2 
expression have used methods that alter genomic and protein expression profiles 
of numerous factors beyond EAAT2. These prior studies have lacked the ability 
to evaluate the specific neuroprotective role of EAAT2. The aim of this study was 
to isolate and study the contribution of astrocytic EAAT2 towards neuroprotection 
under stroke-like conditions. We found that cell type specific modulation of EAAT2
7
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alone can have a profound effect on neuronal survival following excitotoxic insult.
Methods
Virus Preparation
The rAAV1-GFAP-hrGRP and rAAV1-GFAP-EAAT2 viruses were packaged 
in HEK293T cells cultures grown in standard growth media (DMEM, 10% heat 
inactivated FBS, 0.05% penicillin/streptomycin (5000 U/ml), 0.1 mM MEM 
nonessential amino acids, 1 mM MEM sodium pyruvate, and gentamicin (25 
mg/ml)). Cells were transfected with three plasmids using Polyfect Transfection 
Reagent (Qiagen, Valencia, CA). The three plasmids used in the transfection were 
1) adeno helper plasmid (pFA6), AAV helper (H21) and the AAV packaging vector 
containing the glial fibrillary acidic protein (GFAP) promoter followed by either 
humanized Renilla green fluorescent protein (hrGFP) gene (Stratagene, La Jolla, 
CA) or the EAAT2 gene sequence (obtained from J. Rothstein), flanked by AAV2 
inverted terminal repeats. The GFAP-hrGFP construct contained the 3’ Woodchuck 
hepatitis virus post-transcriptional regulation element (WPRE). The WPRE 
construct has been shown to enhance trans-gene expression and viral packaging 
(Loeb, 1999; Paterna, 2000; Hlavaty, 2005). Virus was isolated from HEK293T 
cells through repeated freeze-thaw cycles, incubation for 30 minutes at 37°C 
with 50U benzonase (Novagen, Madison, Wl) and 0.5% sodium deoxycholate, 
briefly sonicated and further purified by iodixonol density gradient centrifugation 
as previously reported (Zolotukhin, 1999). The titer (genomic particles/ml (gp/ml)) 
of final virus isolate was determined by quantitative real time-polymerase chain 
reaction (RT-PCR) using an ABI Prism 7700 with primer and probe sets specific for 
the EAAT2 sequence or the WPRE sequence.
8
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Rat hippocampal slice cultures (RHSC)
The RHSC were prepared using a modified method of Noraberg (1999). 
Hippocampal tissue was isolated from 7-day-old Sprague-Dawley rats. Tissue was 
cut into 350 ^m slices (Mcllwain Vibratome 800, Mickle Laboratory Engineering 
Co., Gomshall, Surrey, UK) and transferred to ice-cold dissection media (Hanks 
balanced salt solution, 20mM HEPES, 25mM D-glucose, pH 7.3, filter sterilized) 
and incubated for 30 minutes on ice. Slices presenting clear hippocampal 
architecture were transferred to dissection media alone or media containing 1 
x 1011 gp/ml rAAV1-GFAP-EAAT2 or rAAV1-GFAP-hrGFP, oxygenated for 30 
minutes and placed on Millipore organotypic inserts in 6-well plates containing 1 
ml of primary RHSC media (50% Optimem (Invitrogen, Carlsbad, CA), 25% HBSS, 
25% heat inactivated horse serum, 25mM D-Glucose, 2.7 jaM amphotercin B, +/- 
100j.iM penicillin G, pH 7.3, filter sterilized). On day three, media was changed to a 
secondary culture media (Neurobasal -A media, B-27 supplement, 1mM Gluta-max 
(Invitrogen, Carlsbad, CA), 25mM D-glucose, 2.7 amphotercin B, +/- 100p,M 
penicillin G, pH 7.3, filter sterilized). Secondary media was changed every 3 days. 
Cultures were maintained at 37°C, 5% C02 for 10 days.
Oxygen and glucose deprivation (OGD)
OGD studies were performed using a modified method of Bonde, et al. 
((Bonde, 2003). Propidium iodide (PI) is a polar compound that gains entry into 
dead and dying neurons and binds to nucleic acid. Binding of PI to DNA results in 
a red fluorescence emission (630nm) upon excitation (495nm). At least 6 hours 
prior to stroke, PI (Molecular Probes, Eugene, OR) was added to the media at a 
concentration of 2p,M (Noraberg, 1999). At this concentration, staining is specific 
for damaged neurons. OGD was simulated by transferring inserts to deoxygenated,
9
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glucose-free balanced salt solution (BSS) (120 mM NaCL, 5mM KCI, 1.25 mM 
Na2HP04, 2mM CaCI2, 25mM NaHC03, 20mM HEPES, 25mM Sucrose, pH 7.3, 
filter sterilized). Cultures were then incubating in an oxygen deprivation chamber 
(37°C, 5% C02 and 95% N2, Biospheric, PRO-OX 110) for 1 hour. After OGD, 
inserts were transferred back into wells with 1 ml secondary media containing 25 
mM D-glucose and PI and returned to normoxic culture conditions. Fluorescent 
images were taken of the hippocampal slices prior to OGD and 6, 12, 18, and 24 
hours post-OGD on an Olympus IMT-2 inverted microscope (Melville, NY) attached 
to an Olympus digital camera using the Magnafire SP software package (Optronics, 
Goleta, CA). Total fluorescent intensity over time was determined using Image Pro 
Plus software (MediaCybernetics, Silver Springs, MD).
Western Blot Analysis
Western blot analysis of rat hippocampal slice cultures were performed to 
evaluate EAAT2 expression levels in control slices, penicillin G treated slices and 
cultures transduced with rAAV1-GFAP-EAAT2. The RHSC were homogenized 
in lysis solution (2.5% sodium deoxycholate, 0.1% protease inhibitor cocktail set 
III (Calbiochem, San Diego, CA), and 0.05% benzonase (EMD Biosciences, San 
Diego, CA) in PBS). Protein concentrations of lysate samples were determined 
using the Bio-Rad DC protein assay (Hercules, CA). Aliquots of homogenized 
RHSC (30p,g) were loaded onto a NuPAGE 4-12% Bis-Tris gel (Invitrogen, 
Carlsbad, CA). Proteins were transferred to Immuno-Blot PVDF membrane (Bio- 
Rad, Hercules, CA) and blocked in Tris buffer containing Tween-20 and 0.5% 
non-fat milk. Membranes were probed with antibodies to GLT-1 (1:500, ABR) and 
actin (1:1000, Sigma, St. Louis, MO). Proteins were visualized using ECL (Pierce, 
Rockford, IL) with species-specific HRP conjugated secondary antibodies. Blots
10
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were imaged on a Kodak Image Station 440 CF. Dosimetry analysis of regions of 
interest were used to calculate fold change in EAAT2 protein expression corrected 
to actin control.
Immunohistochemistry
Cell type specific expression from the GFAP promoter was evaluated 
for rAAV1-GFAP-hrGFP in RHSC. Slice cultures were transduced with rAAV1- 
GFAP-hrGFP and fixed after 10 days in culture. Slices were fixed with 4% 
paraformaldehyde for 30 minutes at room temperature (RT), incubated 2 minutes 
in rinse in ice-cold methanol and stored at 4°C in PBS. Slices were incubated 
in blocking buffer (1.5% normal goat serum, 0.3% Triton-X 100) for 1 hour at 
room temperature (RT). After initial blocking, slices were stained with antibodies 
to NeuN (1:200) or GFAP (1:400) (Chemicon, Temecula, CA) for 1 hour at RT, 
rinsed in blocking buffer and incubated in species-specific conjugated secondary 
antibody (1:200, Molecular Probes, Eugene, OR). Slices were placed onto 
charged glass slides and coverslipped with Fluorosave (Calbiochem, San Diego, 
CA). Images were obtained on a Bio-Rad Radiance 2000 MP laser scanning 
confocal microscope (Hercules, CA).
Functional uptake assays
Uptake assays were performed using a modified method of Selkirk (Selkirk,
2005). Briefly, slices were homogenized on ice in tissue buffer (50mM Tris, 0.3M 
sucrose, pH 7.3) and pelleted at 14,000g for 10 minutes at 4°C. Pellet was 
resuspended in 250pL of either sodium containing Krebs buffer or sodium-free 
Krebs containing equimolar amount of choline. Hippocampal homogenates were
11
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incubated with aspartic acid solution (200nM [3H] D-aspartic acid (PerkinElmer, 
Boston, MA) and 2.0p,M cold D-aspartic acid (Novabiochem, San Diego, CA)) 
in the presence and absence of 0.5 mM dihydrokainic acid (Tocris, Ellisville, 
MO). DHK is an EAAT2 selective uptake inhibitor and allows for assessment of 
non-EAAT2 mediated aspartic acid uptake. Reactions were incubated at 37°C 
for 4 minutes and promptly terminated by filtration through Whatman GC/F filter 
paper (Whatman, Brentford, Middlesex, UK) via Brandel Cell Harvester (Brandel, 
Gaithersburg, MD). Filtrate was incubated overnight in scintillation cocktail and 
counted on a Beckman LS 6500 Scintillation System. Specific EAAT2 mediated 
uptake of [3H]-D-aspartic acid was calculated as total sodium-dependent uptake 
less the uptake in the presence of EAAT2 inhibitor, DHK.
Data Analysis
One-way ANOVA was performed to determine statistical significance of 
western blot dosimetry analysis, functional [3H]D-aspartic acid uptake and level 
of neuroprotection offered between the control tissue and those treated with 
either penicillin G or transduced with rAAV-GFAP-EAAT2. Statistical analysis was 
performed using Prism Software (GraphPad Software, Inc., San Diego, CA).
Results 
Astrocyte specific transgene expression
The GFAP promoter sequence identified by Brenner et. al. has been used 
in multiple studies to selectively drive protein expression in astrocytes (Brenner 
1994). Feng et. al. demonstrated stable, long-term astrocyte specific expression 
of apolipoprotein E (ApoE) using rAAV containing the GFAP promoter (Feng,
12
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2004). Guo et. al. utilized the GFAP promoter sequence to drive EAAT2 expression 
in a transgenic mouse model (2003) and noted a high degree of astrocyte specific 
transgene expression.
The rAAV1-GFAP-hrGFP virus was used to validate cell type specificity of 
the rAAV1-GFAP viral construct. Rat hippocampal slice cultures were transduced 
with rAAV1-GFAP-hrGFP and immunostained with anti-NeuN or anti-GFAP to 
identify neurons and astrocytes, respectively. Use of rAAV1-GFAP-hrGFP in RHSC 
revealed an astrocyte specific expression of hrGFP evident by co-localization of 
hrGFP expression and anti-GFAP staining. No co-localization was noted between 
hrGFP expression and NeuN staining (Figure 1).
Increased expression of functional EAAT2
Western blot analysis was performed to assess the level of induced 
EAAT2 expression in RHSC. Transduction of RHSC with rAAV1-GFAP-EAAT2 
significantly increased EAAT2 expression by 129% over that of control (Figure 
2A). Similarly, treatment of RHSC with lOO^M penicillin rendered a statistically 
significant increase in EAAT2 expression of 63% over that of control. Total 
intensity of all three bands characteristic of EAAT2, consisting of a monomer, dimer 
and multimeric aggregated proteins, were used to calculate total band intensity. 
Additionally, each lane was calibrated to an actin control to account for variations 
in total protein added in each lane. Levels of EAAT1, EAAT3 and EAAT4 remained 
unchanged (data not shown).
To determine if the induced EAAT2 expression was functional, we compared 
[3H]D-aspartic acid uptake levels between control, penicillin G and rAAV1-GFAP- 
EAAT2 transduced RHSC. Synaptosomal preparations from rAAV1-GFAp-EAAT2 
and penicillin G treated slices showed a 62% and 28% increase, respectively, in
13
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DHK sensitive uptake over controls (Figure 2B). The disparity between the level 
of increased EAAT2 expression to that noted in EAAT2 specific uptake may be 
attributed to western blot analysis quantifying total EAAT2 levels, which would 
include both immature intracellular transporters and mature functional transporters 
on the cells surface.
Increased astrocytic EAAT2 expression is neuroprotective
To evaluate the potential neuroprotective contribution of EAAT2 under 
excitotoxic conditions, oxygen-glucose deprivation studies were performed 
on control RHSC compared to penicillin G treated and rAAV1-GFAP-EAAT2 
transduced slices. Elevated astrocytic EAAT2 expression, whether mediated by 
rAAV1-GFAP-EAAT2 or penicillin G, offers neuroprotection under OGD conditions. 
Propidium iodide is taken up specifically by dead and dying neurons when present 
in concentrations less than 2^M (Noraberg, 1999). Elevated EAAT2 levels resulted 
in statistically significant decrease in PI uptake at each of the 4 time points imaged 
post-OGD compared to control (Figure 3). No statistically significant difference 
in PI uptake was noted prior to OGD. The level of neuroprotection was similar 
between the two treatment groups at each of the observed time points compared 
to control.
Discussion
Prior studies have established GFAP promoter driven cell type specific 
protein expression in astrocytes. Feng et. al. used a similar viral construct to 
drive stable, long-term ApoE expression in astrocytes (Feng, 2004). Guo et. al. 
developed a transgenic mouse model using the GFAP promoter to drive EAAT2 
expression (Guo, 2003). Over expression of EAAT2 during development in these
14
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transgenic animals reduced life-span, litter size and overall growth. A true measure 
of EAAT2 mediated neuroprotection could not be conclusively defined by this study 
due to the potential shift in CNS development in this transgenic model. The use 
of rAAV to mediate changes to EAAT2 expression limits complications noted by 
altering essential glutamate signaling during developmental processes (Lujan,
2005). Results presented here demonstrate efficient astrocyte specific EAAT2 
over-expression through the use of rAAV1-GFAP viral constructs.
Prior attempts at modifying EAAT2 function and expression in astrocytes 
have been limited to non-specific or indirect approaches. Pharmacological 
agents available for study of select glutamate transporters offer modest selectivity 
between the multiple glutamate transporter variants, mild potency, are unable to 
target transporters in a cell type specific manner and, most importantly, are limited 
to inhibition of transporter function. More recently, multiple agents have been 
identified that cause an upregulation of astrocytic EAAT2 expression. An increase 
in astrocytic EAAT2 expression in tissue pre-treated with p-lactam antibiotics 
was recently reported (Rothstein, 2005). Rothstein et. al. suggested that 
Ceftriaxone, the p-lactam of focus in their study, mediated neuroprotection through 
a mechanism similar to ischemic preconditioning (IPC). Treatment of tissue with 
FK506 and its non-immunosuppressive derivative, GPI-1046, both activators of the 
neuroimmuniphilin FK506-binding protein (FKBP12), has recently been reported to 
cause an increase in EAAT2 expression (Ganel, 2006; Labrande, 2006). Treatment 
with FK506 causes shifts in protein expression in peripheral and CNS tissue similar 
to that noted with IPC, such as upregulation of HSP70 and downregulation multiple 
of pro-apoptotic pathways (Yang, 2003; Furuichi, 2004). Upregulation of EAAT2 is 
just one of numerous pathways altered in IPC (Stenzel-Poore, 2003; Carmel, 2004; 
Romera, 2004). Previously identified components altered in the IPC response
15
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have been shown to invoke neuroprotection when introduced individually, including 
erythropoietin, ceramide, TNFa and TNFa-convertase (Liu, 2000; Ruscher, 2002; 
Dirnagl, 2003; Romera, 2004). These single components of IPC initiate a cascade 
of changes similar to IPC established through an acute non-lethal excitatory 
stimulus. This limits the ability of these prior studies to specifically evaluate the 
direct impact of EAAT2 over-expression in neuroprotective pathways altered 
under IPC and neuroimmunophilin activation (Dirnagl, 2003; Stenzel-Poore, 2003; 
Yang, 2003; Furuichi, 2004). The use of rAAV1-GFAP-EAAT2 enables direct over­
expression of astrocytic EAAT2 and assessment of the direct role this glutamate 
transporter plays in neuroprotection under oxygen-glucose deprivation.
Specific over-expression of EAAT2 in astrocytes is neuroprotective under 
oxygen glucose deprivation. Prior studies have shown upregulation of EAAT2 
correlates with neuroprotection but were unable to conclusively state the direct 
impact of EAAT2 on neuroprotection due to the simultaneous activation of other 
neuroprotective pathways (Rothstein, 2005; Ganel, 2006; Labrande, 2006). 
The aim of this study was to isolate one component altered under IPC, namely 
the upregulation of EAAT2, and evaluate the role of this glutamate transporter 
in neuroprotection. Our results demonstrate the neuroprotective potential of 
astrocytic EAAT2 through direct and exclusive over-expression of this glutamate 
transporter in astrocytes.
Neuroprotection mediated by penicillin G treatment and transduction 
with rAAV1-GFAP-EAAT2 most likely occurs through different mechanisms. 
Presumably, the two approaches may invoke similar genomic and proteomic 
changes that occur as a result of increased EAAT2 expression and through 
the heightened removal of glutamate from the synaptic cleft under excitotoxic 
conditions. Pathways leading up to and causing increase on EAAT2 expression
16
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in astrocytes may differ considerably between antibiotic treated and rAAV1-GFAP- 
EAAT2 transduced slices. Ischemic preconditioning, the proposed mechanism 
behind neuroprotection noted with p-lactam antibiotic treatment, is a response to 
an acute, sub-lethal excitotoxic event. Penicillin G is an antagonist at the GABA-A 
receptor (Fujimoto, 1995). Inhibition of this receptor is thought to invoke a dose 
dependent excitotoxic event through continued glutamate release. Penicillin G 
has been shown to cause a spike in glutamate release and is commonly used 
to induce seizure at higher doses (Shen and Lai, 2002). Moderate dosing of 
penicillin G may elicit the required acute, sub-lethal excitatory event needed to 
initiate IPC. This initial excitotoxic event could cause numerous changes to both 
genomic and proteomic expression (Dirnagl, 2003; Stenzel-Poore, 2003; Carmel, 
2004; Romera, 2004). Upregulation of GABA-A receptor, hypoxia inducible factor- 
1 (HIF-1), glucose transporters, and tumor necrosis factor alpha (TNFa), and 
downregulation of glutamate receptors, transcriptional activators, and vesicular 
docking proteins are just a few of the proteins altered in IPC (Liu, 2000; Ruscher, 
2002; Sommer, 2002; Dirnagl, 2003; Stenzel-Poore, 2003; Carmel, 2004; Romera, 
2004; Dave, 2005; Lu, 2005). The direct over-expression of EAAT2 through 
the use of rAAV1-GFAP-EAAT2 bypasses activation of the additional pathways 
associated with IPC. The direct mechanisms mediating neuroprotection in rAAV1- 
GFAP-EAAT2 transduced tissue has yet to be defined. Full-scale proteomic and 
genomic analyses are required to definitively identify deviations and commonalities 
between IPC and rAAV1-GFAP-EAAT2 mediated neuroprotection.
Three mechanisms may collectively contribute to the observed 
neuroprotection offered through over-expression of astrocytic EAAT2 with rAAV1- 
GFAP-EAAT2. First, increased EAAT2 membrane expression limits excitotoxicity 
by removal of glutamate and termination of post-synaptic excitatory signaling
17
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(Danbolt, 2001). Increasing the ability of astrocytes to remove glutamate from 
the synaptic cleft through increased EAAT2 expression may produce a refined 
or hypoactive glutamate signaling environment. Under low glutamate signaling 
conditions mediated by low glutamate synaptic concentrations or through use 
of glutamate receptor antagonists, glutamate receptors have been shown to 
shift in subunit composition and signaling potential (Molnar and Isaac, 2002). In 
extreme conditions, hypofunctional glutamate signaling has been observed to 
cause disruption in learning and memory and induce schizophrenia like behavior 
(Farber, 2003). While over-expression of EAAT2 may offer neuroprotection under 
excitotoxic events, the potential for hypofunctional glutamate signaling and altered 
glutamate receptor sensitivity has yet to be studied. Second, increased supply 
of glutamate to astrocytes may facilitate an increased production of nutrients and 
antioxidants to neurons (Benarroch, 2005). Astrocytes possess a cystine-glutamate 
exchanger that facilitates accumulation of cystine within the astrocyte. Inside the 
astrocyte cystine is converted to cysteine and used in the astrocytic production of 
glutathione precursor for use by neurons. The glutathione precursor, L-cysteinyl- 
glycine is converted to glutathione in the neuron by interaction with the y-glutamyl 
transpeptidase coenzyme. Additionally, astrocytes are able to regenerate ascorbic 
acid to ascorbate for reuse by neurons (Kim, 2005). Ascorbic acid recycling is 
positively coupled to increased glutamate uptake, glucose utilization and glutathione 
production. Neurons are incapable of producing these potent antioxidants alone. 
Increased glutamate uptake capacity of astrocytes could enhance the supply of 
precursors and energy production required to synthesize these potent antioxidants 
essential for neuronal health. Lastly, a shift in energy production and utilization may 
alter the neuro-metabolic coupling between astrocytes and neurons. Glutamate 
uptake is coupled to a concomitant sodium influx. The Na+/K+ ATPases maintain
18
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an intracellular sodium concentration (10-20 mM) (Kimelberg and Goderie, 1993). 
Increases in intracellular sodium concentrations results in the activation of energy 
consuming Na+/K+ ATPase and stimulates glucose uptake and glycolytic activity. 
Accordingly, activation of these pathways results in an increase in astrocytic lactate 
and pyruvate production and release. Low level increase in supply of lactate to 
neurons has been shown to upregulate pathways involved in lactate utilization and 
promotes enhanced ability to utilize lactate under successive anaerobic conditions 
(Dienel and Hertz, 2005). Together, increase in glutamate uptake initiates these 
cascades resulting in increased energy supply to neurons in the form of lactate 
and to a lesser extent pyruvate. This promotes a neuroprotective environment, 
accumulation of energy reserve and enhanced lactate utilization capacity to be 
used during subsequent oxygen glucose deprivation. These three proposed 
mechanisms of EAAT2 mediated neuroprotection together promote overall health 
of tissue through increased production of anti-oxidants, energy supplies, balanced 
extracellular environment and induce a general energy depletion tolerance.
Together, this study has identified a novel tool, rAAV1-GFAP-EAAT2, that 
enables cell type specific modulation of select glutamate transporter expression. 
While prior studies have shown capacity to increase EAAT2 expression, they 
have done so through indirect means or in a fashion that may cause deleterious 
influences on development. The novel rAAV construct used in this study offers 
the first direct approach to study the role of astrocytic EAAT2 expression in 
neuroprotection and neuropathology of disease. The mechanism in which direct 
over expression of EAAT2 mediates neuroprotection has yet to be fully defined and 
is the focus of ongoing studies.
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Figure 3. Neurodamage mediated by oxygen glucose deprivation (OGD) as 
measured by propidium iodide (PI) uptake in control, rAAV1-GFAP-EAAT2 
transduced and penicillin G treated rat hippocampal slice cultures (RHSC). 
Total average fluorescence was measured at each time point. One-way ANOVA 
analysis, * = p < 0.01, Control (n=26), rAAV1-GFAP-EAAT2 (n=14), Penicillin G 
treated tissue (n=24).
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Chapter Three
EAAC1 glutamate transporter activity on inhibitory presynaptic terminals 
modulates GABA synthesis and neuroprotection.
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Abstract
As the principle inhibitory amino acid, y-animobutyric acid (GABA) functions 
to counter excitatory signaling in the CNS. Excitatory amino acid carrier 1 (EAAC1) 
is present throughout the CNS with a small percentage being uniquely expressed 
on inhibitory presynaptic terminals and provides a primary source of glutamate for 
GABA synthesis. Alterations to this or other pathways leading to GABA synthesis, 
may result in abnormal inhibitory synaptic transmission, neuronal hyperexcitability 
and epileptiform activity. Prior studies have shown GABA synthesis and quantal 
vesicular release were reduced and seizure-like behaviors were heightened 
under pharmacological inhibition or antisense knockdown of EAAC1. The 
approaches taken in these prior studies inhibited EAAC1 expression and function 
on a global scale and lacked the ability to regulate EAAC1 in a cell type specific 
manner. We hypothesized that increased GABAergic EAAC1 expression would 
enhance GABA synthesis and promote neuroprotection. Results presented here 
demonstrate that increasing EAAC1 expression causes an increase in GABA 
synthesis. Using recombinant adeno-associated virus vectors, we were able 
to specifically target transgene delivery to GABAergic neurons and direct over­
expression and knockdown of EAAC1 in vivo. To evaluate the impact of altered 
GABA synthesis on seizure susceptibility, the pilocarpine induced seizure model 
was used to study the influence of altered EAAC1 expression on the rate of 
progression of seizure-like behavior as measure by a modified Racine scale and 
the development of neuropathology after tonic-clonic seizures. Modulation of 
GABAergic EAAC1 expression resulted in alterations in both seizure susceptibility 
and neuroprotection.
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Introduction
The principle inhibitory neurotransmitter, yaniinobutyric acid (GABA) 
functions to maintain a fine balance between excitatory and inhibitory signaling 
in the CNS. Disruption to this balance commonly results in a shift favoring 
excitotoxicity resulting in acute neuropathology and chronic neurodegradation 
as noted in Alzheimer’s disease, Huntington’s Disease, amyotryophic lateral 
sclerosis (ALS) and epilepsy (Enterzari-Taher, 1997; Marczynski, 1998; Kleppner 
and Tobin, 2001; Ben-Ari and Holmes, 2005; Cossart, 2005). The key to managing 
the balance between excitatory and inhibitory signaling lies in the ability to control 
GABA synthesis and response to excitotoxic events early in the disease process 
in affected regions.
GABAergic neurons comprise only 10%-20% of the total neuronal 
population in the hippocampus (Ben-Ari and Holmes, 2005). On GABAergic 
neurons, EAAC1 is uniquely localized to presynaptic terminals and provide a 
primary source of glutamate precursor for GABA synthesis (Rothstein, 1994; 
Sepkuty, 2002). Glutamate interacts with the glutamate decarboxylase (GAD) 
enzyme to form GABA (Martin and Rimvall, 1993) in inhibitory neurons. GAD65, 
one of two isoforms found in GABAergic neurons, is membrane associated and 
found in inhibitory presynaptic terminals co-localized with EAAC1 (Conti, 1998).
Prior studies have identified the potential impact of EAAC1 expression and 
function on GABA synthesis and susceptibility to excitotoxic stimulus. General 
antisense knockdown of EAAC1 results in a decrease in GABA synthesis, and 
an increase in seizure-like behaviors and susceptibility to glutamate mediated 
neurodamage (Sepkuty, 2002; Brustovetsky, 2004). Quantal vesicular release of 
GABA is reduced in the presence of non-specific glutamate transport inhibitors
as observed through attenuation of mIPSC recordings (Mathews and Diamond
31
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2003). In contrast, increased GABA synthesis and vesicular loading results 
from elevated synaptic glutamate levels and functional glutamate uptake. These 
results collectively suggest a protective role of EAAC1 that enables an increase in 
GABA synthesis in response to high synaptic glutamate levels. While these prior 
studies identified the potential role of altered EAAC1 expression and function in 
GABA synthesis, the approaches used to modulate EAAC1 lacked the ability to 
specifically isolate and study the small percentage of EAAC1 uniquely expressed 
on GABAergic neurons. A means to exclusively alter the expression and function 
of EAAC1 localized to inhibitory presynaptic terminals is needed to definitely study 
the impact of this transporter on GABA synthesis and inhibitory signaling.
The aim of this study was to evaluate the influence of cell type specific 
modulation of EAAC1 expression on GABA synthesis and the impact of altered 
inhibitory response on seizure susceptibility and neuroprotection. Through HPLC 
analysis, increased EAAT3 expression in a GABAergic neuronal cell line was 
shown to effectively alter the intracellular concentrations of glutamate and GABA. 
A recombinant adeno-associated virus (rAAV) was developed using the GAD65 
promoter sequence to drive cell type specific EAAC1 expression in GABAergic 
neurons in vivo. This novel viral construct was used to selectively increase and 
knockdown EAAC1 expression in inhibitory presynaptic terminals and evaluate 
the impact of GABAergic EAAC1 expression on seizure susceptibility and 
neuropathology.
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Methods
Plasmid Design and Virus Preparation
Rat cortical tissue was used to produce cDNA using the Cells-to cDNA II kit 
(Ambion, Austin, TX). Primers were designed for amplification of the rat GAD65 
promoter sequence (Skak and Michelsen, 1999). Upstream primer contained 
a Kpnl restriction site: 5’-GGTACCGGCGCTCCGCAG-3’ and a downstream 
primer containing a Bell restriction site: 5’-TGATCAGGGTTCTGCTAGTCTGG- 
3’. Amplified products were cloned into the TOPO Blunt PCR cloning plasmid 
(Invitrogen, Carlsbad, CA) and fragments confirmed by double stranded sequence 
analysis. The promoter sequence was subcloned into the Kpnl and BamHI 
sites of the pAM-hrGFP-WPRE vector. Three additional GAD65 plasmids were 
designed containing an EAAC1 tagged with a flag epitope (DYKDDDK) on the 
5’ end (flag-EAAC1), an EAAC1 in the antisense orientation (EAAC1 AS), or an 
empty expression cassette (Null). Rat cDNA was used to PCR amplify the flag- 
EAAC1 sequence with upstream primer containing an Xhol restriction site and 
the flag epitope: 5’-CTCGAGATGGATTATAAAGATGACGATGACAAATGTATGG 
GGAAGCCCACGAG-3’ and downstream primer containing a Hindlll restriction 
site: 5’-AAGCTTAGGCATCTAAGGCCAGGC-3’. The constructs contained the 3’ 
Woodchuck hepatitis virus post-transcriptional regulation element (WPRE). The 
WPRE construct has been shown to enhance trans-gene expression (Loeb, 1999; 
Paterna, 2000; Hlavaty, 2005). The GAD65 promoter and expression cassettes are 
flanked by AAV serotype 2 (AAV2) inverted terminal repeats. Prior studies have 
shown chimeric rAAV at select serotype ratios increases overall viral infectivity 
(Rabinowitz, 2004). For this study, we used a 3:1 ratio of serotype 1 to serotype 
2 .
The four pAM-GAD65 plasmids, containing the Null, EAAC1 AS and flag-
EAAC1 expression cassettes, and one pAM-CAG-EAAT3 plasmid (Esslinger, 2005)
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were used in the production of rAAV. HEK293T cells cultures were transfected with 
the pAM-GAD65 and pAM-CAG constructs using Polyfect Transfection Reagent 
(Qiagen, Valencia, CA) (Selkirk, 2005). For the production of the rAAV1-CAG- 
EAAT3-WPRE virus, the three plasmids used in the transfection were 1) pFA6 
(adenoviral helper plasmid), 2) pH21 (cap gene for AAV serotype 1 and rep gene 
for serotype 2) and 3) the AAV plasmid containing the CAG promoter upstream 
from the EAAT3-WPRE sequence. For the production of the chimeric AAV1/2- 
GAD65 viruses, the four plasmids were used in the transfection were 1) pFA6 
(adenoviral helper plasmid), 2) pH21 (cap gene for AAV serotype 1 and rep gene 
for serotype 2), 3) pRVI (cap and rep genes for AAV serotype 2), and 4) the AAV 
plasmid containing the GAD65 promoter upstream from the flag-EAAC1, EAAC1 
AS, Null or hrGFP gene sequence, flanked by AAV2 inverted terminal repeats.
Virus was isolated from HEK293T cells through repeated freeze-thaw 
cycles, incubation for 30 minutes at 37°C with 50U benzonase (Novagen, Madison, 
Wl) and 0.5% sodium deoxycholate, briefly sonicated and further purified by 
iodixonol density gradient centrifugation as previously reported (Zolotukhin, 1999). 
The titer (genomic particles/ml (gp/ml)) of the final virus isolate was determined 
by quantitative real time-polymerase chain reaction (RT-PCR) using an ABI Prism 
7700 with primer and probe sets specific for the cis-acting enhancer WPRE 
sequence.
HC2S2 Cell Line
HC2S2 cells are an immortalized rat GABAergic cell line (kindly provided 
by Dr. Fred H. Gage, Salk Institute, La Jolla, CA) and were cultured as previously 
reported (Hoshimaru, 1996; Asahi, 1998). Briefly, cells were maintained in 
growth media (DMEM/F-12 (50:50) media containing glutamine, N2 supplement
(Invitrogen, Carlsbad, CA), bFGF at 20ng/ml, and amphotercin B in flasks coated
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with poly-l-ornithine and mouse laminin (Invitrogen, Carlsbad, CA). To initiate 
differentiation, cells were plated on coated 12 well plates at 1.0 x 104 cells/well 
in differentiation media (DMEM/F-12 (50:50) media containing glutamine, N2 
supplement (Invitrogen, Carlsbad, CA), bFGF at 2ng/ml, amphotercin B and 20 
ng/ml tetracyline). Tetracycline was added daily to cell culture media at 20pg/ml. 
After 3 days, cells stopped dividing and began to send out neuronal processes. 
HC2S2 cells were transduced with rAAV1-CAG-EAAT3 on day 3 in culture with 5.0 
x 105 gp/cell. Cells were maintained in culture media which was changed every 
other day for 10 days.
Functional Uptake Analysis
[3H]D-Aspartic-acid (PerkinElmer, Boston, MA) uptake was used to assess 
functional EAAT3 mediated activity. Seven days post transduction with rAAV1- 
CAG-EAAT3, differentiation media was removed and HC2S2 cells were gently 
rinsed with pre-warmed sodium-containing HEPES buffer (20mM HEPES, 120 
mM NaCI, 5mM KCI, 1mM KH2P04, 2mM CaCI2, 10mM D-glucose, pH 7.4) or 
a sodium-free HEPES Buffer (20mM HEPES, 120 mM choline, 5mM KCI, 1mM 
KH2P04, 2mM CaCI2,10mM D-glucose, pH 7.4). Media was replaced with HEPES 
+/- sodium containing 100nM [3H]D-aspartic acid and incubated for 4 minutes at 
37°C. Uptake was terminated by the removal of [3H]D-aspartic acid containing 
media, rinsed twice in ice cold sodium-free HEPES and cells were lysed in lysis 
solution (0.1 N NAOH, 0.01% SDS). Aliquots of the lysate were collected, incubated 
in liquid scintillation cocktail and counted for measure of [3H]D-aspartic acid on 
a Beckman LS 6500 Scintillation System. Specific EAAT3 mediated uptake of 
[3H]-D-aspartic acid was calculated as total sodium-dependent uptake less the 
uptake in the absence of sodium and reported as pmol/mg protein/min. Protein
concentration was determined on sister wells using the Bio-Rad DC protein assay
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(Hercules, CA).
Western Blot Analysis
Western blot analysis of the HC2S2 cell cultures were performed to 
evaluate EAAT3 expression levels in control cells and cells transduced with 
rAAV1-CAG-EAAT3. Cells were removed from 12 wells plates and homogenized 
in lysis solution (2.5% sodium deoxycholate, 0.1% protease inhibitor cocktail set 
III (Calbiochem, San Diego, CA), and 0.05% benzonase (EMD Biosciences, San 
Diego, CA) in PBS). Protein concentrations of lysate samples were determined 
using the Bio-Rad DC protein assay (Hercules, CA). Aliquots of homogenized 
HC2S2 cells (30|ig) were loaded onto a NuPAGE 4-12% Bis-Tris gel (Invitrogen, 
Carlsbad, CA). Proteins were transferred to Immuno-Blot PVDF membrane (Bio- 
Rad, Hercules, CA) and blocked in Tris buffer containing Tween-20 and 0.5% non­
fat milk. Membranes were probed with antibodies to EAAT3 (1:1000, ADI, San 
Antonio, TX) and actin (1:1000, Sigma, St. Louis, MO). Proteins were visualized 
using ECL (Pierce, Rockford, IL) with species-specific HRP conjugated secondary 
antibodies. Blot was imaged on a Kodak Image Station 440 CF. Dosimetry 
analysis of all three bands, representing different multimers of EAAT3, were used 
to calculate fold change in EAAT3 protein expression corrected to actin control.
High-Performance Liquid Chromotography (HPLC) analysis
HPLC analysis was performed to evaluate the total intracellular
concentrations of specific amino acids in control or rAAV1-CAG-EAAT3 transduced
HC2S2 cells. Cells were lysed in 0.1 N perchloric acid solution, centrifuged at
14,000g for 10 minutes at 4°C and supernatant was retained. Protein concentrations
were determined using the Bio-Rad DC microplate protein assay (Hercules, CA).
Samples (10p,L) were derivatized with an o-phtaldialdehyde (OPA) solution (90p.L)
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and 40|J of the derivatized sample was loaded for HPLC analysis.
Detection of amino acid content was performed by HPLC using anAmersham 
Bioscience AKTA purifier system (GE Healthcare, Piscataway, NJ)., equipped with 
a Spherisord 5piM ODS1 reverse phase column (4.6x250mm, Waters Corporation, 
Tokyo Japan). Amino acid levels were quantified by fluorescence detection at 440 
nm (emission) and 330nm (excitation). Mobile phase A was composed of 0.03M 
sodium acetate and 1% tetrahydrofuran. Mobile phase B was compose of 0.02M 
sodium acetate in 80% acetonitrile. Amino acids were separated using a linear 
increase in concentration of mobile phase B from 0% to 40% over 40 minutes at a 
flow rate of 0.8 ml/min. Retention time for GABA, glutamate and glutamine (Sigma, 
St. Louis, MO) were 29, 8, 23 minutes respectively as confirmed by amino acid 
standards. Specific concentrations were determined through analysis of amino 
acid standards over an applicable range of concentrations.
Animal Stereotaxic Injections
Eight-week old male Sprague-Dawley rats (200-250g) were anesthetized 
by brief isoflurane inhalation (Abbott Laboratories, North Chicago, IL) and 
intramuscular injection of ketamine (100mg/kg of body weight, Vetus Animal 
Health, Westbury, NY) then placed into a stereotaxic frame (Stoelting, Wood Dale, 
IL) and were maintained on 1.0 LPM of oxygen and 2% isoflurane. Injections were 
performed from the following coordinates beginning at midline of the bregma: - 
3.3mm dorsal from midline of the bregma, +/- 1.8mm lateral and -3.0mm depth 
from surface of the brain. The four rAAV1/2-GAD65p vectors (hrGFP, Null, EAAC1 
AS, and flag-EAAC1,1 x 1013 gp/ml) were diluted 1:1 with 25% mannitol (American 
Regent Inc., Shirley, NY) and 8 îl was delivered to each hippocampus at a rate of 
0.5 p,l/min.
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Seizure Study
Four weeks post rAAV bilateral stereotaxic injections, animals were evaluated 
for seizure susceptibility. The pilocarpine solution (100mg/ml, BioChemika, Buchs, 
Switzerland) and atropine (100mg/ml, Sigma, St. Louis, MO) solution were 
prepared in a 0.9% saline solution, pH adjusted to 7.4 and filter sterilized. Thirty 
minutes prior to pilocarpine treatment, each animal received 100mg/kg atropine 
intraparitoneal (IP) to limit peripheral effects of pilocarpine. Pilocarpine solution 
was delivered I.P. at a concentration of 300mg/kg body weight. Animals were 
monitored and seizure-like behavior determined based on a modified Racine scale 
(Racine, 1972b; Sperk, 1994). The behaviors were broken down into the following 
stages: 1) chewing, salivation, walking backwards, 2) head bobbing, tremors, wet- 
dog shakes, 3) forearm clonus, rearing/falling, 4) 1 class 5 seizure 5) 3+ class 5 
seizures and 6) general tonic-clonic behavior, status epilepticus. Time to reach 
each stage was recorded for each animal and times were averaged between 
animals within the same treatment group. Sixty minutes post-onset of SE animals 
received 10mg/kg body weight of Diazepam (Abbott Laboratories, North Chicago, 
IL).
Immunohistochemistry
Brain tissues were harvested from non-seizure animals at 4 weeks post 
surgery and from animals that progressed to SE in the seizure study 48 hours after 
onset of SE. Animals were anesthetized with isoflurane and perfused with 4% 
paraformaldehyde, decapitated and brain tissue removed. Tissue was incubated 
post harvest for 24 hours in 4% PFA, placed in 30% sucrose solution and stored at 
4°C until cryosectioning. Tissue was sectioned on a cryostat (Thermo Shandon, 
Pittsburg, Pa) into 40^m slices, placed on charged slides, briefly dehydrated in
100% ethanol and stored at 4°C until use.
38
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Cell type specific expression was evaluated for rAAV1/2-GAD65p-hrGFP 
and rAAV1/2-GAD65p-flag-EAAC1 in cryosectioned brain slices of non-seizure 
animals. Slices were incubated in blocking buffer (1.5% normal goat serum, 0.3% 
Triton-X 100) for 1 hour at room temperature (RT). After initial blocking, slices 
were stained with antibodies to GAD65 (1:300) or flag epitope (DYKDDDK) (1: 
1000) (Chemicon, Temecula, CA) for 1 hour at RT, rinsed in blocking buffer and 
incubated in species-specific conjugated secondary antibody (1:200, Molecular 
Probes, Eugene, OR). Slices were coverslipped with Fluorosave (Calbiochem, 
San Diego, CA). Images were obtained on a Bio-Rad Radiance 2000 MP laser 
scanning confocal microscope (Hercules, CA).
A marker for neurodegradation, Fluoro-Jade B (Histo-Chem, Inc., Jefferson, 
AR), was used to evaluate the level of seizure mediated damage. Tissue was 
processed as previously published (Wang, 2000). Briefly, cryosectioned tissue 
was incubated in 1% sodium hydroxide and 80% ethanol solution for 5 minutes, 
rinsed in 70% ethanol for 2 minutes, and rinsed in distilled water for an additional 
2 minutes. Tissue was then incubated with gentle agitation in 0.06% potassium 
permanganate for 10 minutes, rinsed with distilled water and incubated in 0.0004% 
FluoroJade B working solution for 20 minutes. Tissue was rinsed with distilled 
water and allowed to dry in a 37°C incubator over-night. Slides were immersed 
in xylene for 1 minute and coverslipped with DPX. Tissue was imaged using an 
Olympus IMT-2 inverted fluorescent microscope attached to an Olympus digital 
camera (Olympus, Melville, NY) and captured using Magnafire SP imaging 
software package (Optronics, Goleta, CA). Total fluorescent intensity per region of 
interest was determined using Image Pro Plus software (MediaCybernetics, Silver 
Springs, MD).
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Data Analysis
One-way ANOVA was performed to determine statistical significance of 
western blot dosimetry analysis, functional [3H]D-aspartic acid uptake and level 
of Fluoro-Jade B staining between the control tissue and transduced tissue. 
Statistical analysis was performed using Prism Software (GraphPad Software, 
Inc., San Diego, CA).
Results
EAAT3 expression regulates intracellular GABA, glutamate and glutamine 
levels
Prior studies have demonstrated the influence of global EAAC1 knockdown 
or pharmacological inhibition on GABA synthesis and signaling (Sepkuty, 2002; 
Mathews and Diamond, 2003; Brustovetsky, 2004). No prior studies have 
effectively analyzed the potential for increased GABA synthesis associated with 
increase in cell type specific EAAC1 expression. Therefore, to investigate the 
impact of elevated EAAC1 (EAAT3) expression on GABA synthesis, we used 
rAAV1-CAG-EAAT3 to increase functional EAAT3 expression in a GABAergic 
cell line and measured neurotransmitter levels through HPLC analysis. Western 
blot analysis and functional uptake assays were performed to assess the level 
of increased EAAT3 expression and functionality of the recombinant transporter. 
Western blot analysis indicated a 6-fold increase in EAAT3 expression (Figure 1A) 
in HC2S2 cells transduced with rAAV1 -CAG-EAAT3 over that of control cultures. 
Functional [3H]D-aspartic acid uptake increased 4-fold in HC2S2 cells transduced 
with rAAAVI-CAG-EAAT3 over that of control, non-transduced HC2S2 cells 
(Figure 1B). Discrepancy between the total EAAT3 expression level and increase in 
uptake may be attributed to partial sub-cellular localization characteristic of EAAT3
(Krizman-Genda, 2005). Together, these initial studies validated functionality of
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rAAV1-CAG mediated EAAT3 over-expression.
To further test the hypothesis that EAAT3 expression regulates GABA 
synthesis, intracellular amino acid content of HC2S2 cells transduced with rAAV1- 
CAG-EAAT3 were measured by HPLC analysis. GABA levels, as determined by 
HPLC, increased 136% over that measured in non-transduced HC2S2 cells (Figure 
2A). Additionally, elevated EAAC1 levels resulted in a 56% increase in glutamate 
(Figure 2B) and 146% increase in glutamine (Figure 2C) intracellular levels when 
compared to non-transduced HC2S2 cells. Increased intracellular glutamate levels 
would be anticipated with increased functional EAAT3 expression and enhanced 
capacity for uptake of glutamate from the extracellular space (Figure 1A and 1B). 
To support further studies, a virus needed to be developed to enable selective 
modulation of EAAC1 expression in inhibitory presynaptic terminals.
In vivo cell type specific transgene expression
In addition to prior studies (Sepkuty, 2002; Mathews and Diamond, 2003), 
our in vitro results strongly suggested that in vivo modulation of EAAC1 expression 
in GABAergic neurons could alter GABA synthesis. To test this hypothesis, 
we generated an rAAV vector that carried an expression clone in which the 
GAD65 promoter was used to alter EAAC1 expression exclusively in inhibitory 
presynaptic terminals. Initial studies were performed with rAAV1/2-GAD65-hrGFP 
to determine cell type specificity of the viral construct. Adult Sprague-Dawley 
rats were sterotaxically injected with rAAV1/2-GAD65-hrGFP bilaterally into each 
hippocampus. Four weeks post injection, tissue was harvested and cryosections 
were stained with an anti-GAD65 antibody to confirm cell type specificity of 
transgene expression (Figure 3A). GAD65 is localized to GABAergic terminals and 
staining for this protein renders a punctate staining pattern. In the dentate gyrus of
the hippocampus, GABAergic terminals are concentrated on pyramidal neurons.
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The dentate gyrus was chosen for imaging due to the high level of GABAergic 
neurons as compared to other regions in the hippocampus. The hrGFP expression 
was co-localized with GAD65 in GABAergic neuron terminals (Figure 3A).
Utilizing the GAD65 promoter sequence, we designed rAAV vectors that 
facilitated over-expression and knockdown of EAAC1 in inhibitory neurons. EAAC1 
is uniquely expressed on presynaptic terminals and co-localizes with GAD65 (Conti, 
1998) (Figure 3B). Adult Sprague-Dawley rats received either the null, EAAC1 AS 
or flag-EAAC1 virus through stereotaxic injections in each hippocampus. Four 
weeks post injection, tissue was harvested and cryosectioned. Tissue transduced 
with rAAV1/2-GAD65-Flag-EAAC1 was dual stained with antibodies against GAD65 
and the flag epitope. Figure 3C indicates that the flag-EAAC1 protein co-localized 
with GAD65. Images taken of tissue transduced with rAAV1/2-GAD65-EAAC1 AS 
did not reveal detectable differences in EAAC1 expression (data not shown). Due 
to the limited sensitivity of standard immunohistochemical techniques, knockdown 
of this protein could not be efficiently detected. We would predict that the antisense 
virus would knockdown, but not completely knockout, EAAC1 expression within 
inhibitory neurons. In addition, EAAC1 present in postsynaptic terminals of 
glutamatergic pyramidal neurons would also be detected in immunohistochemical 
staining. These immunohistochemical studies further support cell type specific 
expression patterns mediated by rAAV1/2-GAD65 viral constructs and indicates 
that recombinant EAAC1 proteins are trafficked to the proper subcellular location.
Modulation of EAAC1 expression on inhibitory presynaptic terminals 
influences seizure sensitivity and neuroprotection.
We hypothesized that over-expression of EAAC1 in inhibitory presynaptic 
terminals would result in increased GABA production, leading to reduced sensitivity
to pilocarpine induced seizures and neuropathology. In contrast, we hypothesized
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that knockdown of GABAergic EAAC1 expression would lead to reduced GABA 
production, increased sensitivity to pilocarpine-induced seizures and increased 
neuropathology. To test these hypotheses, we used the pilocarpine induced seizure 
model to further assess the impact of GABAergic EAAC1 expression on seizure 
susceptibility. Age-matched adult male Sprague-Dawley rats, transduced with 
rAAV1/2-GAD65-Null (Null), rAAV1/2-GAD65-EAAC1 AS (EAAC1 AS), or rAAV1/ 
2-GAD65-flag-EAAC1 (Flag-EAAC1) and non-transduced controls, received IP 
injections of pilocarpine (300mg/kg) and were monitored for progression through 
distinct behavioral stages leading to status epilepticus (SE) (Racine, 1972a; 
Racine, 1972b; Sperk, 1994).
Overall, 40% of control, 23% of Null, 100% of EAAC1 AS and 50% of Flag- 
EAAC1 treatment groups progressed to SE. The number of animals reaching SE 
were similar between the control, Null and flag-EAAC1 treated groups, whereas 
100% of animals in the EAAC1 AS treatment group progressed to SE. The control 
and the null treatment group progressed to SE at similar rates and reached SE 
at 16.97 +/- 0.91 and 23.68 +/- 0.88 minutes, respectively (Figure 4). In contrast, 
the rate at which EAAC1 AS treated animals progressed to SE was reduced by 
almost one half (11.28 +/- 0.65 minutes). Significant differences in the rate of 
progression were noted at stage 4 and stage 6. Commonly, control and null 
treated animals experienced 3+ seizures prior to entering SE. On average, the 
EAAC1 AS treatment group progressed to stage 4 (1 class 5 seizure) and directly 
progressed to tonic-clonic seizure. In contrast, the flag-EAAC1 treatment group 
advanced through the stages leading to SE at a significantly slower rate (42.02 
+/- 2.42 minutes) compared to all other treatment groups. Requiring almost twice 
as long to reach SE compared to both the control and null treatment groups and 
almost four times slower than EAAC1 AS treated animals. Statistical significant
differences were noted between the Flag-EAAC1 treatment group and control at
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stages 4, 5 and 6.
A similar pattern of altered neuropathology was observed in the brains 
of animals that had progressed to status epilepticus. A stain specific for 
neurodamage, Fluoro-Jade B, was used to quantify degree of seizure mediated 
neuronal cell damage. Brain tissue was harvested 48 hours after the onset of 
SE from representative animals from each of the treatment groups. The relative 
level of Fluoro-Jade B staining within the hippocampus and cortex was determined 
from each group of animals. Observations were made from similar regions of the 
hippocampus and cortex. Seizure-mediated neuropathology was similar between 
controls and animals transduced with the Null virus (Figure 5A, 5B). However, 
tissue transduced with rAAV1/2-GAD65-flag-EAAC1 revealed significantly less 
neurodamage compared to control tissue. In contrast, knockdown of EAAC1 
with rAAV1/2-GAD65-EAAC1 AS increased overall measured neuronal damage 
compared to control tissue. The differences in neuroprotection were most striking 
within the CA1 region of the hippocampus. It is worth noting that all four groups 
showed similar levels of Fluoro-Jade B staining within the cortex (Figure 6).
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Discussion
Prior studies have attempted to study the role of EAAC1 expression and 
function on GABA signaling. Sepkuty et. al. used an oligonucleotide antisense 
method to knockdown EAAC1 expression globally. A severe 50% decline in 
GABA synthesis was observed in antisense treated animals. This associated 
loss of EAAC1 expression and diminished GABA synthesis resulted in increased 
epileptiform activity evident from EEG recordings. This study went on to report 
visual observation of seizure-like behaviors (staring episodes, forearm clonus) that 
correlated with observed EEG changes. Electrophysiology of antisense treated 
tissue showed an increase in hyperexcitability characterized by spontaneous 
burst in spike activity. From these results, Sepkuty et. al. suggested the potential 
impact of restricted EAAC1 expression in epilepsy. Additional studies by Mathews 
et. al. used a pharmacological approach to further elucidate the parameters of 
EAAC1 in GABA synthesis. Miniature inhibitory postsynaptic currents (mIPSC) 
were diminished in the presence of general glutamate uptake inhibitors but not 
in the presence of GLT-1 specific blockers. Similarly, quantal load of vesicular 
GABA release was reduced in the presence of these inhibitors. In contrast, in 
the presence of elevated synaptic glutamate concentrations the strength of GABA 
inhibition form a single vesicular release was increased. These studies suggested 
cytosolic GABA content may influence extent of vesicular loading and quantal 
release of GABA. While these prior studies provided insight into EAAC1 regulation 
of GABA synthesis, the inability to selectively target EAAC1 localized to GABAergic 
neurons was a primary drawback. From these prior studies, the potential for 
increased GABA synthesis and subsequent increase in tonic inhibition through 
over-expression of EAAC1 on inhibitory presynaptic terminals was suggested.
Prior attempts to alter EAAC1 expression have been limited to global
inhibition of function and expression (Sepkuty, 2002; Mathews and Diamond,
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2003). Pharmacological inhibition lack the ability to isolate and inhibit EAAC1 
mediated glutamate uptake from other glutamate transporter variants much less a 
select subpopulation of EAAC1 localized to GABAergic neurons. Similarly, studies 
utilizing antisense oligonucleotide knockdown of EAAC1 have lacked cell type 
specificity of the ability to selectively increase expression of GABAergic EAAC1 
(Sepkuty, 2002; Brustovetsky, 2004). These previous studies were essential in 
identifying the potential influence of EAAC1 expressed on inhibitory presynaptic 
terminals in GABA synthesis and the impact of EAAC1 activity on seizure 
susceptibility, but were limited in their ability to make conclusive statements about 
GABAergic EAAC1 specifically. To effectively study the role of EAAC1 localized to 
presynaptic inhibitory neurons, a methodology enabling cell type specific targeting 
and direct modulation of EAAC1 expression was required.
The novel design of the rAAV1/2-GAD65 viral constructs offers cell type 
specific targeting of transgene expression to GABAergic neurons The use 
of this viral construct to direct the over-expression and knockdown of EAAC1 
located on inhibitory presynaptic terminals. Difficulty was noted in observing 
or measuring extent of EAAC1 AS mediated knockdown due to high level of 
EAAC1 background expression on non-GABAergic neurons and the sensitivity 
of available immunohistochemical techniques. The best means of evaluating the 
role of restricted EAAC1 expression was through an in vivo approach. These viral 
constructs offer the ability to selectively target and modulate protein expression 
in this small subset of hippocampal neurons. To our knowledge, these results 
illustrate the first successful attempt to regulate EAAC1 expression specific to 
GABAergic neurons.
We hypothesized that over-expression of EAAT3 (EAAC1) may increase 
the supply of glutamate precursor and result in increased GABA synthesis. To
test this hypothesis, we evaluated the role of this glutamate transporter in GABA
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synthesis in a GABAergic HC2S2 neuronal cell line. Prior studies have noted the 
limited cell-surface expression of EAAC1 (Fournier, 2004). Therefore, we wanted 
to determine whether increased expression of EAAC1 would result in increased 
cell surface expression. The increase in EAAC1 expression resulted in increased 
[3H]D-aspartic acid uptake. This data strongly suggest that functional recombinant 
EAAT3 (EAAC1) is localized in the plasma membrane and is functional. HPLC 
analysis of intracellular amino acid content in HC2S2 cells transduced with rAAV1- 
CAG-EAAT2 revealed significant increased in GABA, glutamate and glutamine 
compared to control cultures. The shift in glutamate levels can be directly attributed 
to increased EAAT3 (EAAC1) mediated glutamate uptake capacity as evident 
from increased uptake of [3H]D-aspartic acid. Increased glutamine levels may be 
caused by inhibition of mitochondrial uptake in the presence of elevated glutamate 
levels. Glutamate has been shown to competitively inhibit mitochondrial uptake 
of glutamine and offers an alternative mechanism for negative feedback in the 
production of glutamate in neurons (Roberg, 1999). Together, these data suggest 
that increased EAAC1 membrane surface expression on GABAergic neurons 
increases intracellular levels of glutamate promote enhanced GABA synthesis. 
This increase in intracellular GABA may increase vesicular loading and quantal 
release of GABA as suggested by Mathews and Diamond (2003). Increased 
quantal release of GABA may enhance the strength of the inhibitory response to 
pilocarpine-induced excitotoxicity.
Neuronal connectivity between the entrohinal cortex and the hippocampus 
provides the initiation point of excitatory signaling in the disinhibition leading to 
epileptiform activity (lire and Perassolo, 2000). Axons from the cortex lead into 
the outer layer of the dentate gyrus (DG) which contains the highest concentration 
of GABAergic neurons within the hippocampus (da Silva, 2005). Excitatory signal
passes through the layers of the DG and flow into the pyramidal neurons of the CA3.
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The CA3 neurons feed the excitatory signal to the CA1 pyramidal neurons. Exiting 
of the excitatory signal from the CA1 to the entrohinal cortex completes this cyclic 
path. Disinhibition of this circuit lends to formation and propagation of epileptic 
discharges. Altered response to pilocarpine administration would be observed 
by shifting the ability of GABAergic inhibition to stop or hinder this cyclic epileptic 
discharge. We observed that expression of EAAC1 changes the threshold of 
seizure susceptibility and rate of progression to SE. Animals transduced with flag- 
EAAC1 progressed to SE at a significantly slower rate and exhibited significantly 
less neuropathology. This may be attributed to increased capacity to withstand 
pilocarpine mediated excitatory stimulus due to elevated GABA supply and 
increased inhibitory postsynaptic strength. Increased GABA synthesis may enable 
extended inhibitory signaling during cyclic epileptic discharge. In contrast, animals 
transduced with EAAC1 AS progressed to SE at an accelerated rate. Inability of 
the GABAergic neurons within the DG to counter incoming excitatory signalling 
following pilocarpine administration would increase excitatory signaling through 
the CA3 and CA1 regions of the hippocampus. These data suggest the ability to 
modulate susceptibility to seizure through the regulation of EAAC1 expression in 
inhibitory presynaptic terminals.
An alternative pathway which has been shown to amplify GABA release 
under excitotoxic conditions has been identified. Reversal of neuronal GABA 
transporters (GAT-1) under excitotoxic stimulation has been observed (Haugstad, 
1997; Allen, 2004). Increased intracellular levels of GABA may additionally exit 
inhibitory terminals through this mechanism and further potentiate inhibitory 
signaling. Animals that received EAAC1 AS progressed to status epilepticus at 
a significantly faster rate. The inability of these animals to withstand the cyclic 
epileptic discharge resulting in seizure may be due to diminished capacity for
GABA synthesis that may result in restricted vesicular and GAT-1 mediated GABA
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release. Likewise, upregulation of EAAC1 expression would enhance these same 
factors mediating level of GABA release. Together, these results strongly support 
the essential role of EAAC1 in GABA synthesis and altered expression of this 
glutamate transporter in seizure susceptibility.
Patterns of neurodamage noted in each of the treatment groups follow the 
excitatory signaling pathways in the hippocampus (Ure and Perassolo, 2000). 
Overall neurodamage within the hippocampus, as identified through Fluoro- 
Jade B staining, was significantly decreased in the flag-EAAC1 transduced 
tissue. Increased capacity for GABA synthesis through the upregulation of 
EAAC1 expression may contribute to neuroprotection under pilocarpine induced 
seizures. In contrast, measure of total neurodamage in the hippocampus of tissue 
transduced with EAAC1 AS revealed a significant increase in seizure-mediated 
neurodegradation. Following the signaling pathways in the hippocampus, altered 
inhibitory capacity of the DG and CA3 would shift the excitatory signaling entering 
the hippocampus to inflict the highest degree of damage on the CA1 region. The 
CA1 region has been shown to have the lowest number of GABAergic neurons 
and GAD65 positive neuron processes and appears to be the most susceptible to 
seizure mediated damage in the EAAC1 AS treated animals. Together, our results 
show the over-expression of Flag-EAAC1 offers neuroprotection under pilocarpine- 
induced seizures. Likewise, the knockdown of EAAC1 results in heightened level of 
neurodamage under pilocarpine-mediated seizure activity. These results suggest 
the significant impact of altered EAAC1 expression and function in epileptogenesis 
and resulting seizure mediated damage.
The aim of this study was to evaluate the impact of GABAergic EAAC1 
expression on GABA synthesis and seizure susceptibility. We showed elevated 
levels of EAAC1 expression results in increased GABA synthesis and altered
intracellular concentrations of glutamate and glutamine. We developed a tool
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enabling cell type specific targeting and manipulation of GABAergic neuron 
protein expression through the over-expression and knockdown of EAAC1 in 
vivo. This tool presents the only currently available mechanism for targeting this 
small subset of hippocampal neuron populations. The over-expression of EAAC1 
offers significant neuroprotection under pilocarpine-mediated seizure activity. This 
neuroprotection is thought to be the result of increased GABA synthesis capacity 
and may result in altered vesicular loading and release of GABA. The knockdown 
of EAAC1 resulted in a significant increase in seizure-mediated neurodamage and 
is thought to be a result of restricted GABA synthesis conditions. Together, this 
study presents the first data suggesting the direct correlation between EAAC1 
expression in inhibitory presynaptic terminals, GABA synthesis capacity and 
altered response to pilocarpine-induced seizure susceptibility.
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Figure 1. Increased functional expression of EAAT3 in HC2S2 cells transduced 
with rAAVI-CAG-EAAT3. A) Western blot analysis of non-transduced control 
HC2S2 cells (C) and cells transduced with rAAVI-CAG-EAAT3 (CE3) probed with 
antibody to EAAC1. B) Dosimetry analysis of western blot of EAAT3 in HC2S2 
cells transduced with rAAVI -CAG-EAAT3 compared to control and corrected actin. 
C) Functional EAAT3 mediated uptake of [3H]D-aspartic acid in non-transduced 
HC2S2 cells or cells transduced with rAAVI-CAG-EAAT3. Specific sodium- 
dependent glutamate transporter uptake of [3H]D-aspartic acid was determined 
as the difference in uptake in the presence and absence of sodium. * = p < 0.01,
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Figure 2. HPLC analysis of control and rAAVI-CAG-EAAT3 transduced HC2S2 
cultures revealed a significant alteration in A) GABA, B) glutamate and C) 
glutamine. * = p < 0.01, n=6
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Figure 3. Cell type specific expression mediated by rAAVI/2-GAD65 viral 
constructs. A) Tissue transduced with rAAVI/2-GAD65-hrGFP and immunostained 
with an antibody against GAD65. The hrGFP expression co-localizes wth GAD65 
in GABAErgic neuron terminals. The arrows indicate co-localization of hrGFP 
expression and GAD65 staining in the inhibitory presynaptic terminals (40x). B) 
Control tissue stained to demonstrate normal EAAC1 co-localization with GAD65. 
C) Tissue transduced with rAAVI /2-GAD65-flag-EAAC1 was stained with an 
antibody against the flag epitope located on the 3’ terminus of the recombinant 
EAAC1 transporter and anti-GAD65. Within the dentate gyrus, flag staining co­
localized with GAD65 staining. Images B & C were obtained at 100x.
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Figure 4. EAAC1 expression altered seizure susceptibility and rate of progression 
to SE. The pilocarpine induced seizure model was used to evaluate altered state 
of seizure susceptibility as a function of EAAC1 expression on inhibitory neuron 
terminals. Control (■), Null (A), EAAC1 AS (•), and flag-EAAC1 ( ♦ )  animals 
were monitored for progression through distinct behavioral stages based on a 
modified Racine scale. Time to reach each of the stages was noted, averaged for 
each treatment group for animals that reached SE. * = p<0.05, One way ANOVA, 
n=2-7.
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Figure 5. Modulation of EAAC1 expression on inhibitory presynaptic terminals influences 
neuroprotection. A) Tissue was harvested 48 hours post onset of status epilepticus. Tissue from 
each treatment group, control, null, EAAC1 AS and flag-EAAC1, were stained with Fluoro-Jade B 
and imaged to identify the level of seizure-mediated neurodamage. B) Total fluorescence intensity 
of the entire hippocampus was calculated. One-way ANOVA * = p<0.05, n=2-7.
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Chapter Four
Conclusion
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The data presented here offers only a glimpse at the potential of rAAV 
as a tool in the study of glutamate transporters. Recent advances in rAAV 
vector design and the identification of new serotypes offer additional regulatory 
features in the study of glutamate transporters (McCown, 2005; Shevtsova, 
2005; Broekman, 2006). The use of chimeric rAAVI 12 may enable enhanced 
delivery and heightened EAAT2 expression beyond that currently achieved with 
the rAAV serotype 1 (Rabinowitz, 2004). Neonatal delivery of rAAV8-GFAP- 
EAAT2 may facilitate global upregulation of EAAT2 and allow for evaluation 
of wide-spread astrocytic EAAT2 upregulation (Broekman, 2006), though 
upregulation of EAAT2 during development may alter essential developmental 
processes as evident in a transgenic model over-expressing EAAT2 (Guo, 2003).
Components involved in glutamate processing in astrocytes may influence 
overall glutamate uptake capacity. Glutamine synthetase, the enzyme in astrocytes 
responsible for conversion of glutamate to glutamine, may become saturated under 
heightened intracellular glutamate levels. Likewise, uptake of glutamate via EAAT2 
and conversion to glutamine are energy requiring processes. Components involved 
in energy production or homeostatic maintenance, such as a-ketoglutarate, cystine- 
glutamate transporter, additional enzymes involved in the TCA cycle or glucose 
uptake and utilization may be altered underelevated intracellular levels of glutamate.
A use of alternative GABAergic promoters, such as parvalbumin or GAD67, 
may provide further control of EAAC1 expression levels. Maximum EAAC1 
expression levels may not be optimum in the overall viability of GABAergic 
neurons. Uptake of glutamate by EAAC1 localized to inhibitory presynaptic 
neurons is an energy dependent process and may result in rapid energy 
depletion under extended excitotoxic stimulus. By inducing graded expression 
levels of EAAC1 on GABAergic neurons, one may be able to regulate or post-
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pone energy depletion and maximize the inhibitory potential of GABAergic 
neurons. Further study is needed to evaluate the impact of each of these factors 
on sustained glutamate uptake and cell viability under excitotoxic conditions.
Multiple factors impacted by altered intracellular glutamate levels may 
influence the level of functional glutamate uptake. Modulation of other factors 
involved in GABA synthesis may provide insight into the limiting steps of the 
synthesis pathway. We demonstrated that the upregulation of EAAC1 on inhibitory 
presynaptic terminals resulted in elevated intracellular GABA, glutamate and 
glutamine levels. The elevated level of GABA precursor, glutamate, may saturate 
GAD65 synthesis capacity. This could be further evaluated through the simultaneous 
over-expression of GAD65 in GABAergic neurons or through the addition of the 
GAD65 co-factor, pyridoxal-5-phosphate (vitamin B6). Other components may 
influence GABA synthesis capacity in the presence of elevated EAAC1 expression, 
such as glutaminase, components of the TCA cycle or sodium/potassium ATPases.
Lastly, the rAAV1/2-GAD65 viral constructs may prove beneficial in 
evaluating the role of EAAC1 in the development and progression of epilepsy. The 
EAAC1 is upregulated in status epilepticus (Crino, 2002) and has shown elevated 
expression in regions of seizure-mediated damage (Voutsinos-Porche, 2006). It 
has yet to be determined if increased GABAergic EAAC1 expression is a protective 
mechanism under epileptic conditions or is a contributing factor in the ongoing 
damage. Using the viral constructs and methodologies detailed in this dissertation, 
one could evaluate the impact of long term elevated EAAC1 expression in 
GABAergic neurons to further elucidate the function of EAAC1 in epileptigenesis.
Together, these studies revealed the neuroprotective nature of glutamate 
transporters when over-expressed in a cell type specific manner. The rAAVI- 
GFAP and rAAV1/2-GAD65 viral constructs address prior limitations in the
63
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study of glutamate transporters (Sepkuty, 2002; Mathews and Diamond, 2003;
Rothstein, 2005) and offer a means to further evaluate the role of glutamate
transporter expression in neuroprotection and neurodegenerative disease states.
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